Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Lutetium‐177‐dotatate (177Lu‐dotatate), a form of peptide receptor radionuclide therapy, was approved by the U.S. Food and Drug Administration for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (NETs) in 2018 based on the promising results of th...

Full description

Saved in:
Bibliographic Details
Published inThe oncologist (Dayton, Ohio) Vol. 25; no. 8; pp. e1246 - e1248
Main Authors Zhu, Mojun, Bassam Sonbol, Mohamad, Halfdanarson, Thorvardur, Hobday, Timothy, Ahn, Daniel, Ma, Wen Wee, Bekaii‐Saab, Tanios
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.08.2020
Subjects
Brief Communications
Humans
Intestinal Neoplasms
Neuroendocrine Tumors - drug therapy
Neuroendocrine Tumors - genetics
Neuroendocrine Tumors - radiotherapy
Octreotide - therapeutic use
Radioisotopes
Receptors, Peptide
Recombinational DNA Repair
Online AccessGet full text

Cover

More Information
Summary:Lutetium‐177‐dotatate (177Lu‐dotatate), a form of peptide receptor radionuclide therapy, was approved by the U.S. Food and Drug Administration for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (NETs) in 2018 based on the promising results of the NETTER‐1 trial for grade 1–2 midgut NETs. Here, we present a patient with a grade 3 pancreatic neuroendocrine tumor and BRCA1 germline mutation who had a significant response to 177Lu‐dotatate. This article describes a patient with high‐grade pancreatic neuroendocrine tumor and BRCA1 germline mutation who had a significant response to Lutetium‐177‐Dotatate and summarizes the current state of clinical management of high‐grade neuroendocrine tumors.
Bibliography:.
Disclosures of potential conflicts of interest may be found at the end of this article
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Disclosures of potential conflicts of interest may be found at the end of this article.
No part of this article may be reproduced, stored, or transmitted in any form or for any means without the prior permission in writing from the copyright holder. For information on purchasing reprints contact Commercialreprints@wiley.com. For permission information contact permissions@wiley.com.
ISSN:1083-7159
1549-490X
1549-490X
DOI:10.1634/theoncologist.2020-0029